Oncologic Outcomes After Transoral Robotic Surgery
John R. de Almeida(Princess Margaret Cancer Centre), F. Christopher Holsinger(Stanford University), Michael E. Kupferman(The University of Texas MD Anderson Cancer Center), Eric M. Genden(Icahn School of Medicine at Mount Sinai), Vikas Mehta(King's College London), Richard V. Smith(Albert Einstein College of Medicine), Ryan Li(Stanford University), Umamaheswar Duvvuri(City University of New York), Dennis H. Kraus(Memorial Sloan Kettering Cancer Center), Ian Ganly(Memorial Sloan Kettering Cancer Center), Hilliary N. White(University of Alabama at Birmingham), Yoon Woo Koh(Yonsei University), Edward J. Damrose, Marc Remacle(Université Paris-Saclay), Brett A. Miles(Icahn School of Medicine at Mount Sinai), Robert L. Ferris(University of Pittsburgh), Steven J. Wang(University of California, San Francisco), K. Kiyosaki(Cedars-Sinai Medical Center), Georges Lawson(UCLouvain), Eric J. Moore(Mayo Clinic), Marita S. Teng(Icahn School of Medicine at Mount Sinai), J. Scott Magnuson(AdventHealth Orlando)
Cited by 308
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590